首页> 外文学位 >Investigation on permeation of CPT-11 acid versus lactone and optimization of transmucosal delivery of CPT-11
【24h】

Investigation on permeation of CPT-11 acid versus lactone and optimization of transmucosal delivery of CPT-11

机译:CPT-11酸与内酯的渗透研究及CPT-11透粘膜递送的优化

获取原文
获取原文并翻译 | 示例

摘要

CPT-11 is a water soluble camptothecin derivative with broad spectrum of antitumor activities. The therapeutic use of CPT-11 is limited due to its dose limiting toxicity of severe grade 3-4 diarrhea. CPT-11 in the body is converted to its active form SN-38 by the action of carboxylesterases enzyme. Intravenous route of CPT-11 administration at its MTD leads to higher levels of SN-38 in the body which causes diarrhea. Oral administration can be used to lower the dosage of CPT-11. However oral leads to lower bioavailability due to first pass metabolism. An alternative route of delivery which would has the advantages of intravenous and oral but has side-effects of neither is critical.;This research intends to prove that transmucosal (buccal) is a preferred alternative to conventional routes of CPT-11 delivery. The specific aims of this dissertation were: 1) To understand the fundamental physicochemical properties of CPT-11, 2) To establish and validate parameters for in vitro permeation of CPT-11 across porcine buccal mucosa, 3) To characterize the fundamental transport properties of CPT-11 across the buccal mucosa, 4) To study the effect of penetration enhancers on CPT-11 permeability and transport across the buccal membrane and 5) To evaluate the feasibility for buccal delivery of CPT-11 in vivo in rabbits.;CPT-11 was analyzed in mobile phase and rabbit plasma by a validated HPLC method. In order to optimize delivery and to enhance its efficacy, a detailed physicochemical characterization of CPT-11 was carried out. Molecular and system properties were determined by partition and solubility studies using UV spectroscopy and HPLC. Also solid state characterization of CPT-11 was carried out using DSC, XRD and FTIR. Spectral scans of various pH solutions of CPT-11 revealed that the pKa of quinoline moiety was 1.09.Equilibrium hydrolysis revealed that only 13% CPT-11-lactone is present at physiological pH. Distribution coefficient increases with increase in pH, with log D of 0.72 at pH 7.4. Equilibrium solubility decreases from pH 4 -- 9.The hydrolysis of CPT-11-lactone to carboxylate at pH 7.4 follows a pseudo first order kinetics.;To characterize the nature of permeation of CPT-11, in-vitro transmucosal studies were designed to evaluate the feasibility and this included the release of drug at different pH, donor concentration or using multitude of penetration enhancers. Porcine buccal mucosa was used for all of these studies. The pH studies showed that it had no effect on the permeability coefficient of CPT-11 in the range of pH 4.0 to pH 9.0. This indicates the CPT-Ms predominately transported through the paracellular route. Concentration dependency study demonstrated that the steady state flux increased linearly with increasing the donor concentration (0.5 -- 15 mg/ml) at pH 4 and (0.5 -- 10 mg/ml) at pH 6.8. Steady state flux plotted against donor concentration was linear indicating that CPT-11 permeated passively through the buccal mucosa.;Evaluating the permeation of the two form of CPT-11 through the buccal mucosa revealed that the lactone form had two fold higher permeability in comparison to the carboxylate form. This showed that the active form of the drug was delivered through the buccal mucosa. Out of the 16 transcellular and paracellular enhancers studied at donor pH of 4.0, the ones with a significant impact were 1% Transcutol, 20% PEG, 20% PG, 1 mM Sodium deoxycholate, 2% Tween 80 and combination of 10% ethanol and 30% PG. Enhancers were also studied for their penetration effects at donor pH of 9.0, but none showed any significant change.;The in-vivo studies conducted on rabbits showed that the maximum plasma concentration at 10 mg/kg IV infusion reached a maximum of 10 mg/mi. and dropped to 0.75 mg/ml in 8 h. Mean values of systemic clearance was 1086.15mlfh while t 1/2 was 2.77h and distribution volume at steady state was 3481.25 ml. These studies showed that rabbit is a better model for predicting clearance of CPT-11 for humans compared to dogs and other rodents. This aspect of the investigation could not demonstrate systemic delivery of CPT-11 in rabbits. However, the observed GI toxicity in rabbits that received CPT-11 suggests potential metabolic conversion of CPT-11 in the buccal membrane.
机译:CPT-11是具有广泛抗肿瘤活性的水溶性喜树碱衍生物。 CPT-11的治疗用途受到限制,因为它对严重的3-4级腹泻具有剂量限制毒性。体内的CPT-11通过羧酸酯酶的作用转化为其活性形式SN-38。在其MTD时静脉注射CPT-11会导致体内SN-38含量升高,从而引起腹泻。口服可用于降低CPT-11的剂量。然而,由于首过代谢,口服导致较低的生物利用度。具有静脉和口服优点但无副作用的另一种给药途径是至关重要的。这项研究旨在证明经粘膜(颊)是常规CPT-11给药的优选替代方法。本文的具体目的是:1)了解CPT-11的基本理化特性,2)建立和验证CPT-11在猪颊粘膜中体外渗透的参数,3)表征CPT-11的基本转运特性。 CPT-11穿过颊粘膜,4)研究渗透促进剂对CPT-11渗透性和跨颊膜运输的影响,以及5)评估兔体内CPT-11颊内递送的可行性。通过验证的HPLC方法在流动相和兔血浆中分析了11种。为了优化递送并增强其功效,对CPT-11进行了详细的理化表征。分子和系统性质是通过使用紫外线光谱和HPLC进行的分配和溶解度研究确定的。还使用DSC,XRD和FTIR对CPT-11进行了固态表征。 CPT-11的各种pH溶液的光谱扫描显示,喹啉部分的pKa为1.09。平衡水解表明,在生理pH下仅存在13%的CPT-11-内酯。分布系数随pH的增加而增加,在pH 7.4时log D为0.72。从pH值4到9平衡溶解度降低。在7.4的条件下,CPT-11-内酯水解为羧酸盐遵循假一级动力学。为了表征CPT-11的渗透性质,设计了体外透粘膜研究评估可行性,其中包括在不同的pH值,供体浓度或使用多种渗透促进剂的情况下释放药物。所有这些研究均使用猪颊粘膜。 pH研究表明,在pH 4.0至9.0的范围内,它对CPT-11的渗透系数没有影响。这表明CPT-M主要通过细胞旁途径转运。浓度依赖性研究表明,稳态通量随着pH 4的供体浓度(0.5-15 mg / ml)和pH 6.8的供体浓度(0.5-10 mg / ml)线性增加。稳态流量与供体浓度成线性关系,表明CPT-11被动地通过颊粘膜渗透;评估两种形式的CPT-11通过颊粘膜的渗透情况表明,内酯形式的渗透率是CPT-11的两倍。羧酸盐形式。这表明药物的活性形式是通过颊粘膜递送的。在供体pH为4.0时研究的16种跨细胞和旁细胞增强剂中,影响最大的是1%Transcutol,20%PEG,20%PG,1 mM脱氧胆酸钠,2%Tween 80以及10%乙醇和PG 30%。还研究了增强剂在供体pH值为9.0时的渗透作用,但没有发现任何明显变化。;对兔子进行的体内研究表明,静脉输注10 mg / kg时最大血浆浓度达到最大10 mg / kg密并在8小时内降至0.75 mg / ml。全身清除的平均值为1086.15mlfh,而t 1/2为2.77h,稳态时的分配体积为3481.25 ml。这些研究表明,与狗和其他啮齿动物相比,兔子是预测人类CPT-11清除率的更好模型。研究的这一方面无法证明CPT-11在兔子中的全身递送。但是,在接受CPT-11的兔子中观察到的GI毒性表明CPT-11在颊膜中可能发生代谢转化。

著录项

  • 作者

    Shah, Vidhi.;

  • 作者单位

    Long Island University, The Brooklyn Center.;

  • 授予单位 Long Island University, The Brooklyn Center.;
  • 学科 Health education.
  • 学位 Ph.D.
  • 年度 2015
  • 页码 143 p.
  • 总页数 143
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号